CBIO — Crescent Biopharma, Inc.

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

Trend Edge Setup Score

Trend Edge rates CBIO Bullish with a Setup Score of 0, net conviction 28, actionability 0. How the Setup Score works →

Total Setup Score0
Directional BiasBullish
Net Conviction28
Actionability0 (in range)

Key signals behind this score

About Crescent Biopharma, Inc.

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$14.32
Market Cap$530M
Float27.0M
Shares Outstanding37.1M
Price/Sales (TTM)44.58
Operating Margin (TTM)-1432.64%
Revenue (TTM)$11.9M
Dividend RateNone

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $10.2M -$51.0M $10.2M -$51.2M
2021 $1.2M -$63.4M $1.2M -$63.2M
2022 $75,000 -$46.7M $75,000 -$47.2M
2023 $10,000 -$36.9M $10,000 -$39.1M
2024 N/A -$48.5M -$35,174 -$44.2M
2025 $10.8M -$154M $10.8M -$150M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Sep 2025 $30.6M -$24.6M
Dec 2025 $10.8M -$92.4M
Mar 2026 $1.0M -$23.3M
Jun 2026 N/A -$24.8M

Ownership & Float

Insider Ownership0.3%
Institutional Ownership82.9%
Short Float11.7%
% of All Funds Holding0.92%
Number of Funds Holding81

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$16.88Near-term / short-term trend
Weekly40-Week SMA$15.94Medium-term trend
Weekly80-Week SMA$15.92Cyclical trend (business cycle)
Weekly200-Week SMA$87.74Secular trend (multi-year)
Monthly10-Month SMA$16.11Near-term monthly trend
Monthly20-Month SMA$16.13Medium-term monthly trend
Monthly40-Month SMA$66.44Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$11.40 support 1.50x 6 months ago
$9.50 support 1.67x 7 months ago

Historical Earnings Reactions (50 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap 0.03% -0.04% 44.00% 10.99% -5.90%
1 Day 0.38% -0.69% 48.00% 19.51% -9.09%
1 Week 3.39% 0.46% 50.00% 153.66% -65.73%
2 Weeks 6.78% 1.23% 54.00% 240.62% -63.24%
1 Month 5.49% -2.08% 48.98% 198.97% -66.16%

Next earnings: November 5, 2026 (33 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan0.2%41.7%12
Feb0.5%53.8%13
Mar-0.9%38.5%13
Apr-4.3%46.2%13
May8.0%46.2%13
Jun-3.1%30.8%13
Jul-6.8%30.8%13
Aug-3.7%46.2%13
Sep-6.4%15.4%13
Oct10.9%50.0%12
Nov29.0%75.0%12
Dec-3.1%25.0%12

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday -0.46% 44.6% 599
Tuesday 0.51% 43.7% 659
Wednesday -0.28% 43.4% 656
Thursday 0.28% 45.6% 643
Friday 0.25% 46.6% 639

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 82.9%

Insider Transactions — Smart Summary

Total insider ownership: 0.3%

12-Month Insider Activity Summary

Total Filings16
Net Value-$1.5M
Net Shares Change2,128,568
% of Float7.9%
C-Suite Filings14
Clusters Detected2

Key Insiders

NameTitleNet ValueFilingsActivity
Fairmount Funds Management LLC +$30.6M 2 2 buy
Brumm Joshua T Chief Executive Officer -$920,842.172 2 N/A
McNeill Jonathan President and COO -$446,910.881 2 N/A
Pinkas Jan Chief Scientific Officer -$23,171.12 1 N/A
Im Ellie Eunkyung Chief Medical Officer -$21,929.81 1 N/A
Bispham Barbara Harlin General Counsel and Corporate Secretary. -$21,911.82 1 N/A
Scalzo Richard William Chief Financial Officer -$20,004.88 1 N/A

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2026-06-23 – 2026-06-23 7 7 -$1.2M 7 C-suite
2026-09-18 – 2026-09-18 7 7 -$285,500.693 7 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-07-20 Fairmount Funds Management LLC +$12.4M Transaction at $14.50, now -1.2%
2025-12-08 Fairmount Funds Management LLC +$18.2M Transaction at $13.41, now +6.8%
2026-06-23 McNeill Jonathan President and COO -$369,676.51 Transaction at $17.99, now -20.4%
2026-06-23 Brumm Joshua T Chief Executive Officer -$761,066.95 Transaction at $17.99, now -20.4%
2026-09-18 McNeill Jonathan President and COO -$77,234.371 Transaction at $16.90, now -15.3%
2026-09-18 Brumm Joshua T Chief Executive Officer -$159,775.222 Transaction at $16.91, now -15.3%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Crescent Biopharma, Inc. (CBIO) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for CBIO on Trend Edge →